The 2009 New Zealand Cardiovascular Guidelines Handbook What’s new?

Slides:



Advertisements
Similar presentations
Chronic kidney disease
Advertisements

Chronic kidney disease
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
CVD risk estimation and prevention: An overview of SIGN 97.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
JBS2 Some highlights from the JBS2 guidelines on prevention of cardiovascular disease in clinical practice Jim McMorran GP trainer Visiting Senior Clinical.
Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Pharmacological Treatment of Hypertension Update 2012.
A raised thyroid stimulating hormone result is associated with an increased rate of cardiovascular events and would benefit from treatment Gibbons V, Conaglen.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
1FHI 360 Nigeria. 2USAID Nigeria
Risk estimation and the prevention of cardiovascular disease SIGN 97.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Shadi Al-Ahmadi. The Presentation will include: Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic.
Automated Patient-Specific Reporting for Chronic Disease Management in the Clinical Laboratory Dr Glenn Edwards MBBS, MD, FRCPA Medical Director, St John.
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
© Copyright 2009 by the American Association for Clinical Chemistry Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals With and Without.
Section IV. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension 2015 Canadian Hypertension Education Program Recommendations.
Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.
Diabetic nephropathy is a clinical syndrome.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
NHS Health Check Training Lauren Seamons – Norfolk LPC October/November 2015.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
WELCOME TO VITALITY WORKS Real solutions that improve physical health and emotional wellbeing where employees feel more productive, engaged and supported.
NICE/BHS Hypertension Guideline Review 28 June 2006 John Barker ESH Clinical Hypertension Specialists European Society of Hypertension Specialist Accreditation.
Probability and odds Suppose we a frequency distribution for the variable “TB status” The probability of an individual having TB is frequencyRelative.
An aortic aneurysm can rupture (dissecting aneurysm) and cause massive blood loss, circulatory shock and rapid death.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Laboratory Testing For Cardiovascular Risk
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
NHS Health Checks Annual review of >20% risk patients Dr Stephen Liversedge – Clinical Lead for Primary care NHS Bolton CCG.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.
Date of download: 6/25/2016 From: Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2013;159(4):
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Section 4: Managing progression of CKD
Copyright © 2015 by the American Osteopathic Association.
Redefining Quality Care in T2DM Patients with CV Disease
From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.
Copyright © 2011 American Medical Association. All rights reserved.
Peak oxygen uptake and prevalence of cardiovascular disease risk factors in breast cancer survivors Lahart1, I.M., Metsios1, G.S., Nevill1, A.M., Kitas1,2,
What’s New in the 2013 ESC/ESH Hypertension Guideline
Chapter 1: CKD in the General Population
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Systolic Blood Pressure Intervention Trial (SPRINT)
Chapter 1: CKD in the General Population
I. Introduction American Journal of Kidney Diseases
Nat. Rev. Cardiol. doi: /nrcardio
Level of risk factor control in the overall sample and by gender
High Blood Pressure in General Practice: Variation and Opportunities South Cheshire CCG (v11) 5th March 2019.
Goals & Guidelines A summary of international guidelines for CHD
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Presentation transcript:

The 2009 New Zealand Cardiovascular Guidelines Handbook What’s new?

 NZGG has updated the Cardiovascular Guidelines Handbook.  There are several changes that may affect day-to-day practice.

Cardiovascular Risk charts  Ages bands on the risk charts now state an age range (i.e. 55–64 years), instead of choosing the age closest to the patient (i.e. 60 years)  Only systolic blood pressure is required for the calculation of risk Charts are now easier to use

Non-fasting bloods may be collected  Fasting blood tests remains recommended practice  Non fasting bloods may be used for: –Chol/HDL ratio –HbA1c Do non-fasting bloods instead of risking losing a patient

Renal disease recognised  People with CKD begin risk assessments 10 years earlier  ACR (albumin:creatinine ratio) and eGFR can be used for assessing renal function

Lipids target lowered  More aggressive treatment may be required  Optimal targets for lipids for those at higher risk changed: –LDL now < 2.0mmol/L (was < 2.5 mmol/L) –Chol/HDL ratio now < 4.0 (was < 4.5) –Cholesterol < 4.0 mmol/L (no change)

New blood pressure target for CKD  More aggressive treatment of BP may be required for people with CKD.  Target < 125/75 mmHg for all people with chronic kidney disease.

Change to frequency of CVD risk assessment  Update recalls for people with a CVD risk of 10–15%  For people with a CVD risk of between 10–15%, recheck every 2 years (was every 5 years).

New Zealand Cardiovascular Guidelines Handbook 2009 Edition. Available from: (downloadable online version plus order form for hard copy).